Relationships between PET and blood plasma biomarkers in corticobasal syndrome.

Autor: Singh NA; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA., Alnobani A; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA., Graff-Radford J; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA., Machulda MM; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA., Mielke MM; Department of Epidemiology and Prevention, Wake Forest University, Winston-Salem, North Carolina, USA., Schwarz CG; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Senjem ML; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Jack CR Jr; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Lowe VJ; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Kanekiyo T; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA., Josephs KA; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA., Whitwell JL; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Jul; Vol. 20 (7), pp. 4765-4774. Date of Electronic Publication: 2024 Jun 17.
DOI: 10.1002/alz.13914
Abstrakt: Introduction: Corticobasal syndrome (CBS) can result from underlying Alzheimer's disease (AD) pathologies. Little is known about the utility of blood plasma metrics to predict positron emission tomography (PET) biomarker-confirmed AD in CBS.
Methods: A cohort of eighteen CBS patients (8 amyloid beta [Aβ]+; 10 Aβ-) and 8 cognitively unimpaired (CU) individuals underwent PET imaging and plasma analysis. Plasma concentrations were compared using a Kruskal-Wallis test. Spearman correlations assessed relationships between plasma concentrations and PET uptake.
Results: CBS Aβ+ group showed a reduced Aβ42/40 ratio, with elevated phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) concentrations, while CBS Aβ- group only showed elevated NfL concentration compared to CU. Both p-tau181 and GFAP were able to differentiate CBS Aβ- from CBS Aβ+ and showed positive associations with Aβ and tau PET uptake.
Discussion: This study supports use of plasma p-tau181 and GFAP to detect AD in CBS. NfL shows potential as a non-specific disease biomarker of CBS regardless of underlying pathology.
Highlights: Plasma phosphorylated tau (p-tau)181 and glial fibrillary acidic protein (GFAP) concentrations differentiate corticobasal syndrome (CBS) amyloid beta (Aβ)- from CBS Aβ+. Plasma neurofilament light concentrations are elevated in CBS Aβ- and Aβ+ compared to controls. Plasma p-tau181 and GFAP concentrations were associated with Aβ and tau positron emission tomography (PET) uptake. Aβ42/40 ratio showed a negative correlation with Aβ PET uptake.
(© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: